AGMB
NASDAQAgomAb Therapeutics NV
AgomAb Therapeutics NV (AGMB) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for AGMB, including 2 press releases and news items, 2 insider trades and 1 SEC filing. The most recent was published Nov 6, 2026.
AGMB rankings
Financial highlights
Full financials- Revenue, FY2025
- €1.61M
- Revenue growth
- +32.1%
- Net income, FY2025
- -€62.55M
- Net margin
- -3887.3%
- Cash
- €86.42M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks33-67%
2026-05-172026-11-08
Mix2390d
- Insider10(43%)
- Other6(26%)
- SEC Filings4(17%)
- Analyst2(9%)
- Offering1(4%)
Activity · 52 weeks6234 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Epstein David R bought $103,500 worth of shares (15,000 units at $6.90), increasing direct ownership by 60% to 40,000 units (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- PRAgomab to Participate in Upcoming Investor ConferencesAntwerp, Belgium, November 4, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Conference. Fireside chat on Tuesday, November 10, 2026 at 3:30 PM ET in Boston, MA.2026 Jefferies Global Healthcare Conference. Wednesday, November 18, 2026 in London, UK.9th Annual Evercore Healthcare Conference. Fireside chat on Tuesday, December 1, 2026 at 4:15 PM ET in Miami, FL.Piper Sandler 38th Annual Healthcare Conference. Fireside chat on Thursday, December 3, 2026 at 12:30 PM
- INSIDERDirector Epstein David R bought $88,800 worth of shares (10,000 units at $8.88) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - AgomAb Therapeutics NV (0002020932) (Filer)
- PRAgomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint -- -- Study initiation represents an important milestone in the development of ontunisertib as a potential first targeted anti-fibrotic treatment for FSCD -- Antwerp, Belgium, October 13, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that the first patient has been dosed in NOV-ERA
- INSIDERDirector Epstein David R bought $44,500 worth of shares (5,000 units at $8.90) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- PRAgomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation-- Open-Label Extension (OLE) Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global NOV-ERA Phase 2b study in FSCD -- -- Agomab-sponsored symposium to discuss the importance of targeting fibro-inflammation in inflammatory bowel disease (IBD) -- Antwerp, Belgium, October 8, 2026 – Agomab Therapeutics NV (‘Agomab’) a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that OLE data of the Phase 2a STENOVA study will be presented in an oral session at United European Gastroenterology (UEG) Week 2026, taking place October 17-20 in B
- INSIDERDirector Epstein David R bought $86,350 worth of shares (10,000 units at $8.64) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- INSIDERChief Financial Officer Kemula Pierre Thadee Victor bought $85,940 worth of shares (10,000 units at $8.59) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- INSIDERChief Executive Officer Knotnerus Tim Jasper bought $94,380 worth of shares (11,000 units at $8.58) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - AgomAb Therapeutics NV (0002020932) (Filer)
- PRAgomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period -- -- Radiological assessment shows trend for fibrotic stricture stabilization over treatment course -- -- Sustained disease control observed across symptoms and disease activity scores in Open-Label Extension Study (OLE) -- -- Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming months -- -- Company to host webcast today at 8:30 a.m. Eastern Time --
- INSIDERSEC Form 4 filed by Director Garcia Marino4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 4 filed by Director Patel Naimish4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Patel Naimish3 - AgomAb Therapeutics NV (0002020932) (Issuer)
- INSIDERSEC Form 3 filed by new insider Garcia Marino3 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients -- -- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end -- Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results o
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsAntwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Company's Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants. "We are grateful for the support of our shareholders and ex
- PRAgomab to Participate in Upcoming Investor ConferencesAntwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.2026 Cantor Global Healthcare Conference. Fireside chat on Friday, September 11, 2026 at 8:00 AM ET in New York, NY.H.C. Wainwright 28th Annual Global Investment Conference. Fireside chat on Tuesday, September 15, 2026 at 2:00 PM ET in New York, NY.Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Wedn
- ANALYSTPiper Sandler initiated coverage on AgomAb Therapeutics NV with a new price targetPiper Sandler initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $60.00
- ANALYSTCantor Fitzgerald initiated coverage on AgomAb Therapeutics NVCantor Fitzgerald initiated coverage of AgomAb Therapeutics NV with a rating of Overweight
- SECSEC Form 6-K filed by AgomAb Therapeutics NV6-K - Agomab Therapeutics NV (0002020932) (Filer)
- PRAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsAntwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026. "We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors," said David Epstein, Chairman of the Board of Agomab. "Marino brings extensive experience building, financing and leading inno
AGMB FAQ
10 questionsWhat is the latest news on AGMB?
In the last 30 days Quantisnow tracked 5 wire items for AGMB: 2 press releases and news items, 2 insider trades and 1 SEC filing. The most recent was published on November 6, 2026.What is AGMB revenue?
AgomAb Therapeutics NV (AGMB) reported €1.61M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 32.1% from the year before.Is AGMB profitable?
No. AgomAb Therapeutics NV reported a net loss of €62.55M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does AGMB have?
AgomAb Therapeutics NV reported €86.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AGMB stock trade?
AgomAb Therapeutics NV (AGMB) is listed on NASDAQ.What sector and industry is AGMB in?
AgomAb Therapeutics NV operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did AgomAb Therapeutics NV go public?
AgomAb Therapeutics NV (AGMB) completed its IPO in 2026.What are analysts saying about AGMB?
AgomAb Therapeutics NV has had 7 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $60.00 price target on 2026-08-25. Recent price targets range from $28.00 to $60.00.What companies are similar to AGMB?
Notable peers in the same industry include AMGN (Amgen Inc.), EXEL (Exelixis Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare AGMB side-by-side with any of them on Quantisnow.How can I track AGMB on Quantisnow?
Quantisnow aggregates AgomAb Therapeutics NV's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGMB to receive live email and push alerts on every new disclosure.